Octapharma

Octapharma is a leading, privately-held global biopharmaceutical company and the world's largest independent plasma fractionator. It develops and commercializes high-quality therapies derived from human plasma and human cell lines for haematology, immunotherapy, and critical care. With a significant global footprint, over 10,000 employees, and €3.5 billion in revenue for 2025, the company combines robust manufacturing, ongoing R&D, and a strategic focus on sustainability and accessibility to serve patients worldwide.

Advanced large-scale plasma fractionation and recombinant protein production using human cell lines, integrated with modern R&D approaches including automation, VHH (nanobody) research, and machine learning.

Octapharma competes in a concentrated global market dominated by a handful of large, integrated plasma companies including Takeda (Shire), CSL Behring, Grifols, and Kedrion. Competition is fierce across plasma collection, manufacturing efficiency, product portfolio breadth, R&D innovation, and global commercial reach.